Global Intravenous Immunoglobulin Market Size, Share, Trends, Demand, Insights, Opportunities, Forecast, 2014–2021

Report Overview

ResearchBeam adds a report titled “Global Intravenous Immunoglobulin Market (By Application, Types and Geography) 2014–2021”. The report provides an in-depth study on the Global Intravenous Immunoglobulin Market trends, opportunities and factors influencing the market.

IVIG is a sterile solution of antibodies collected from healthy donors, which is administered through the veins into the body. Currently, the immunoglobulin industry is growing on account of increasing FDA/EMA approvals and government support. IVIG usage against the conditions within the criteria (i.e. FDA/EMA approved indications) have increased greatly and the largest increase found in Chronic Inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia and immunodeficiency diseases.

In addition, there has been a substantial increase in IVIG prescriptions for the treatment of off-label indications, such as, specific antibody deficiency, Guillain-Barre syndrome, Inflammatory Myopathies and others. However, factors such as the high cost of IVIG treatment, side effects associated with use of IVIG, stringent government regulations and a lengthy product approval process would hamper its market growth. Despite several challenges such as inadequate supply of immunoglobulins, stringent regulatory policies and the high cost associated with IVIG treatments, the global IVIG market would witness notable growth during the forecast period.

Get Full Report On:
http://www.researchbeam.com/intravenous-immunoglobulin-IVIG-market

Global IVIG market is segmented based on its types, application and geography. The application segment includes Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency diseases, Congenital AIDS, Chronic Lymphocytic Leukaemia (CLL), Myasthenia Gravis, Multifocal motor neuropathy, Idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barre syndrome, and others. Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP) holds a dominant share in the market due to a large patient population and the unavailability of effective alternatives for IVIG treatment. Geographically, the report covers five key regions, North America, Europe, Asia Pacific, and LAMEA. Presently, North America occupies a majority of the market followed by the Asia Pacific region.

KEY MARKET SEGMENT:
Global IVIG market is segmented based on the application, types and geography

MARKET BY APPLICATION

Hypogammaglobulinemia Chronic Inflammatory demyelinating polyneuropathy (CIDP) Immunodeficiency diseases Congenital AIDS Chronic Lymphocytic Leukaemia (CLL) Myasthenia Gravis Multifocal motor neuropathy Idiopathic thrombocytopenic purpura (ITP) Kawasaki disease

MARKET BY GEOGRAPHY

North America United States Canada Mexico Europe Germany France United Kingdom Russia Austria Italy

Enquire About Report:
http://www.researchbeam.com/intravenous-immunoglobulin-IVIG-market/enquire-about-report